Long non-coding RNA ARAP1-AS1 promotes the progression of bladder cancer by regulating miR-4735-3p/NOTCH2 axis

References

• Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234–241. doi:10.1016/j.eururo.2012.07.033.
   PubMed Web of Science ®Google Scholar
• Comprehensive molecular characterization of urothelial bladder carcinoma Cancer Genome Atlas Research Network.. Nature. 2014;507:315–322. doi:10.1038/nature12965.
   PubMed Web of Science ®Google Scholar
• Chamie K, Ballon-Landa E, Bassett JC, Daskivich TJ, Leventhal M, Deapen D, Litwin MS. Quality of diagnostic staging in patients with bladder cancer: a process-outcomes link. Cancer. 2015;121:379–385. doi:10.1002/cncr.29071.
   PubMed Web of Science ®Google Scholar
• Chamie K, Litwin MS, Bassett JC, Daskivich TJ, Lai J, Hanley JM, Konety BR, Saigal CS. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013;119:3219–3227. doi:10.1002/cncr.28147.
   PubMed Web of Science ®Google Scholar
• Chou R, Selph SS, Buckley DI, Gustafson KS, Griffin JC, Grusing SE, Gore JL. Treatment of muscle-invasive bladder cancer: A systematic review. Cancer. 2016;122:842–851. doi:10.1002/cncr.29843.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Hendricks R, Svatek R, Bangs R, Hoffman-Censits J, Clement J, Dreicer R, Guancial E, Hahn N, Lerner SP, et al. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the bladder cancer advocacy network clinical trials working group. Cancer. 2013;119:1994–1998. doi:10.1002/cncr.27973.
   PubMed Web of Science ®Google Scholar
• Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng S-L, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558–562. doi:10.1038/nature13904.
   PubMed Web of Science ®Google Scholar
• Zhan Y, Liu Y, Lin J, Fu X, Zhuang C, Liu L, Xu W, Li J, Chen M, Zhao G, et al. Synthetic Tet-inducible artificial microRNAs targeting beta-catenin or HIF-1alpha inhibit malignant phenotypes of bladder cancer cells T24 and 5637. Sci Rep. 2015;5:16177. doi:10.1038/srep16177.
   PubMed Web of Science ®Google Scholar
• Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee I-L, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152–165. doi:10.1016/j.ccr.2014.01.009.
   PubMed Web of Science ®Google Scholar
• Christodouleas JP, Baumann BC, He J, Hwang WT, Tucker KN, Bekelman JE, Tangen CM, Lerner SP, Guzzo TJ, Malkowicz SB, et al. Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer. 2014;120:1272–1280. doi:10.1002/cncr.28544.
   PubMed Web of Science ®Google Scholar
• Casadio V, Molinari C, Calistri D, Tebaldi M, Gunelli R, Serra L, Falcini F, Zingaretti C, Silvestrini R, Amadori D, et al. DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach. J Exp Clin Cancer Res. 2013;32:94. doi:10.1186/1756-9966-32-94.
   PubMed Web of Science ®Google Scholar
• Feng Y, Liu J, Kang Y, He Y, Liang B, Yang P, Yu Z. miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer. J Exp Clin Cancer Res. 2014;33:67. doi:10.1186/s13046-014-0067-8.
   PubMed Web of Science ®Google Scholar
• Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 2006;15(Spec No 1):R17–29. doi:10.1093/hmg/ddl046.
   PubMed Web of Science ®Google Scholar
• Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Reviews Genet. 2009;10:155–159. doi:10.1038/nrg2521.
   PubMed Web of Science ®Google Scholar
• Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Reviews Genet. 2014;15:7–21. doi:10.1038/nrg3606.
   PubMed Web of Science ®Google Scholar
• Ding J, Yeh CR, Sun Y, Lin C, Chou J, Ou Z, Chang C, Qi J, Yeh S. Estrogen receptor beta promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network. Oncogene. 2018. doi:10.1038/s41388-018-0175-6.
   Web of Science ®Google Scholar
• Li Z, Jiang P, Li J, Peng M, Zhao X, Zhang X, Chen K, Zhang Y, Liu H, Gan L, et al. Tumor-derived exosomal lnc-Sox2ot promotes EMT and stemness by acting as a ceRNA in pancreatic ductal adenocarcinoma. Oncogene. 2018;37:3822–3838. doi:10.1038/s41388-018-0237-9.
   PubMed Web of Science ®Google Scholar
• Cao C, Zhang T, Zhang D, Xie L, Zou X, Lei L, Wu D, Liu L. The long non-coding RNA, SNHG6-003, functions as a competing endogenous RNA to promote the progression of hepatocellular carcinoma. Oncogene. 2017;36:1112–1122. doi:10.1038/onc.2016.278.
   PubMed Web of Science ®Google Scholar
• Lu MH, Tang B, Zeng S, Hu CJ, Xie R, Wu YY, Wang S-M, He F-T, Yang S-M. Long noncoding RNA BC032469, a novel competing endogenous RNA, upregulates hTERT expression by sponging miR-1207-5p and promotes proliferation in gastric cancer. Oncogene. 2016;35:3524–3534. doi:10.1038/onc.2015.413.
   PubMed Web of Science ®Google Scholar
• Huang W, Cui X, Chen J, Feng Y, Song E, Li J, Liu Y. Long non-coding RNA NKILA inhibits migration and invasion of tongue squamous cell carcinoma cells via suppressing epithelial-mesenchymal transition. Oncotarget. 2016;7:62520–62532. doi:10.18632/oncotarget.11528.
   PubMedGoogle Scholar
• Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, Deng X, Chen H, Shen B, Peng C, et al. Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene. 2016;35:1575–1584. doi:10.1038/onc.2015.223.
   PubMed Web of Science ®Google Scholar
• Ma L, Tian X, Wang F, Zhang Z, Du C, Xie X, Kornmann M, Yang Y. The long noncoding RNA H19 promotes cell proliferation via E2F-1 in pancreatic ductal adenocarcinoma. Cancer Biol Ther. 2016;17:1051–1061. doi:10.1080/15384047.2016.1219814.
   PubMed Web of Science ®Google Scholar
• Frith MC, Bailey TL, Kasukawa T, Mignone F, Kummerfeld SK, Madera M, Sunkara S, Furuno M, Bult CJ, Quackenbush J, et al. Discrimination of non-protein-coding transcripts from protein-coding mRNA. RNA Biol. 2006;3:40–48.
   PubMedGoogle Scholar
• Chen G, Wang Z, Wang D, Qiu C, Liu M, Chen X, Zhang Q, Yan G, Cui Q. LncRNADisease: a database for long-non-coding RNA-associated diseases. Nucleic Acids Res. 2013;41:D983–6. doi:10.1093/nar/gks1099.
   PubMed Web of Science ®Google Scholar
• Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, Wu L-M, Chen L-M, Zheng -S-S. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol. 2012;29:1810–1816. doi:10.1007/s12032-011-0004-z.
   PubMed Web of Science ®Google Scholar
• Zhang S, Ma H, Zhang D, Xie S, Wang W, Li Q, Lin Z, Wang Y. LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling. Cell Death Dis. 2018;9:742. doi:10.1038/s41419-018-0793-5.
   PubMed Web of Science ®Google Scholar
• Zhang G, Li S, Lu J, Ge Y, Wang Q, Ma G, Zhao Q, Wu D, Gong W, Du M, et al. LncRNA MT1JP functions as a ceRNA in regulating FBXW7 through competitively binding to miR-92a-3p in gastric cancer. Mol Cancer. 2018;17:87. doi:10.1186/s12943-018-0829-6.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zeng X, Wang N, Zhao W, Zhang X, Teng S, Zhang Y, Lu Z. Long noncoding RNA DANCR, working as a competitive endogenous RNA, promotes ROCK1-mediated proliferation and metastasis via decoying of miR-335-5p and miR-1972 in osteosarcoma. Mol Cancer. 2018;17:89. doi:10.1186/s12943-018-0837-6.
   PubMed Web of Science ®Google Scholar
• Li H, Wang X, Wen C, Huo Z, Wang W, Zhan Q, Cheng D, Chen H, Deng X, Peng C, et al. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer. Mol Cancer. 2017;16:169. doi:10.1186/s12943-017-0738-0.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Z, Yao B, Li Q, Wang L, Wang C, Dou C, Xu M, Liu Q, Tu K. Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis. Mol Cancer. 2017;16:123. doi:10.1186/s12943-017-0702-z.
   PubMed Web of Science ®Google Scholar
• Wang K, Jin W, Song Y, Fei X. LncRNA RP11-436H11.5, functioning as a competitive endogenous RNA, upregulates BCL-W expression by sponging miR-335-5p and promotes proliferation and invasion in renal cell carcinoma. Mol Cancer. 2017;16:166. doi:10.1186/s12943-017-0735-3.
   PubMed Web of Science ®Google Scholar
• YiRen H, YingCong Y, Sunwu Y, Keqin L, Xiaochun T, Senrui C, Ende C, XiZhou L, Yanfan C. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer. 2017;16:174. doi:10.1186/s12943-017-0743-3.
   PubMed Web of Science ®Google Scholar